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X chromosome inactivationEBV infects more than 90% of the human population and persists in most individuals as a latent infection
where the viral genome is silenced by host-driven methylation. The lytic cycle is initiated when the viral
protein Zta binds to methylated BRLF1 and BRRF1 promoters. Although studies reveal the role of Zta and
methylation changes in the viral genome upon EBV infection to reactivation, whether Zta plays any role in
alteration of methylation in the host genome remains unknown. Using an inducible model, we demonstrate
that global DNA methylation, based on whole-genome 5-methylcytosine content, and regional DNA
methylation in repetitive elements, imprinting genes and the X chromosome, remains unchanged in response
to Zta expression. Expression of DNAmethyltransferases was also unaffected by ectopically expressed Zta. Our
data imply that alteration of host gene expression following EBV reactivation may reﬂect methylation-
independent Zta-mediated gene activation and not epigenetic modiﬁcation of the host genome.ly growth response factor 1;
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Epstein–Barr virus (EBV) is a gamma-herpesviriane that primarily
infects epithelial cells and B lymphocytes in humans. EBV infects more
than 90% of the human population, and following primary infection
individuals remain lifelong carriers of the virus. Although most carriers
remain asymptomatic, EBV is associated with several lymphoid and
epithelial malignancies including Burkitt's lymphoma [1], nasopharyn-
geal carcinoma (NPC) [2], nasal natural killer (NK)/T cell lymphoma [3],
and various types of peripheral T-cell proliferative diseases/lymphomas
[4,5]. The degree of EBV association varies among different diseases,
ranging from 20% in Burkitt's lymphoma to nearly 100% in undifferen-
tiated nasopharyngeal carcinomas [6,7] and nasal NK/T cell lymphomas
[3]. In addition, EBV-associated malignancies are known by their
variation in incidence in different geographic regions, for example, the
occurrence of NPC [8] and nasal NK/T cell lymphomas [9] are higher in
Asia than in North America and Europe.Although EBV persists in most individuals as a lifelong, asymptom-
atic latentB cell infection, EBVperiodically reactivates and replicates in a
lytic manner in a subset of B cells—a form of infection essential for viral
propagation and transmission [10,11]. In contrast with infection of B
cells by EBV,which results in latent infection and immortalization of the
cell, infection of epithelial cells byEBV results in viral replication and cell
lysis [12]. Reactivation of the latent virus leading to lytic replication and
shedding and transmission of the virus likely occurs in vivo as memory
cells further differentiate—for example, into plasma cells in response to
antigen stimulation. Entry into the lytic cycle is initiatedbyexpressionof
the immediate-early EBV proteins BZLF1 (Zta) and BRLF1 (Rta). The
transcription of both immediate-early genes is initially induced by
stimuli that activate the lytic phase, and Zta and Rta stimulate their own
expression, reciprocally induce each other, and cooperatively direct
downstream expression of EBV lytic genes [11,13]. Although both Zta
andRta are key lytic transactivators, studies have shown that expression
of Zta alone is sufﬁcient to trigger the entire lytic cascade [10] and that
cells carrying Zta mutations do not express the lytic genes and do not
produce virus particles [14].
Current studies indicate that regulation of EBV latent gene
expression occurs through the host genome DNA methylation system,
which allows the virus to maximize its persistence and escape immune
detection [15,16]. Zta is the only transcription factor known to bind
methylated Zta Responsive Element (ZRE) in the viral BRLF1 promoter
(Rp) [17] and in the NA early lytic viral promoter (Nap) [18]. Zta has
some sequence similarity to FOS and Zta binding sites are present in
several cellular gene promoters; thus, it also promotes expression of
Fig. 1. Southern blot analysis of DNA methylation of repetitive elements in Zta-
expressing cells.Genomic DNA isolated from Zta− or Zta+ was digested with MspI or
HpaII and subjected to Southern blot analysis using probes speciﬁc for (A) SINE-Alu
(Left), LINE-1 (Middle), or α-satellite (Right) repetitive sequences. Arrowheads
indicate bands analyzed to compare methylation in Zta− and Zta+ cells. Represen-
tative images are shown. (B) Following Southern blot analysis, relative methylation in
each DNA sample was quantiﬁed by densitometry (see Materials and methods for
details); data reﬂect mean signal ratios from DNA digested by HpaII to that digested by
MspI±SEM from three independent experiments.
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[19]. Although expression of many cellular genes is altered during EBV
reactivation, the underlying mechanism of Zta-induced target gene
transactivation is largely unknown. Elucidation of the molecular
mechanisms responsible for Zta-regulated gene transcription during
the lytic cycle should not only increase our knowledge of EBV–host cell
interactions but also facilitate the development of anti-viral therapies
[20].
The exact mechanism of EBV infection leading to tumorigenesis is
not yet understood, but alteration of DNAmethylation patterns in EBV-
transformed cells [21] or EBV-transfected cells [22] has been docu-
mented. Concurrent detection of global hypomethylation and local
hypermethylation in DNA extracted from tumors suggests that EBV-
associated cancers exhibit uncontrolled expression of oncogenes and
concomitant silencing of tumor suppressor genes [22,23]. In addition,
elevated expression of DNA methyltransferases (DNMTs) has been
shown in various EBV-associated cancers including gastric cancer [24]
andNPC [22]. Furthermore, previous studyalso suggested that recurrent
EBV reactivations may lead to accumulation of genome instability and
promote the tumor progression in NPC [25]. Altogether these studies
indicate thatmethylation changes in the host genome are in association
with EBV and EBV reactivation is an important pathological step toward
tumor development.
Recently, Kalla et al. [26] report that Zta is expressed but fails to
induce the viral lytic cycle in early infection when EBV DNA is
unmethylated; as the viral DNA is progressively methylated through
its host's mechanism of methylating DNA, it is eventually bound by Zta
to transactivate lytic cycle. Although this study thoroughly examined
the role of Zta and methylation changes in the viral genome upon EBV
infection to reactivation, whether Zta plays any active role in alteration
of methylation in the host genome remains unknown. In this study, we
therefore developed several approaches on a whole-genome scale to
explore the relationship between global DNA methylation and the
expression of DNMTs in Zta-expressing cells of EBV-reactivationmodel.
2. Results
2.1. Probe preparation for Southern blot analysis
To detect global DNA methylation levels in HONE-tetonZ cells
treatedwithdoxycycline (Zta+) and original HONE-tetonZ cells (Zta−)
cells [27], highly conserved sequences from LINE-1, Alu, andα-satellite,
which represent the major classes of repetitive motifs in the human
genome, were cloned and subjected to Southern blot analysis. The
cloned LINE-1, Alu, and α-satellite sequences were 540 bp, 218 bp, and
162 bp in length, respectively. BLAST analysis revealed that the cloned
sequences were widely dispersed throughout all human chromosomes.
The LINE-1 probe sequence was evenly represented in almost all
chromosomes except chromosomes 22 and Y (Supplemental Fig. 1A),
and the Alu probe sequence was present in all but the Y chromosome
(Supplemental Fig. 1B). Theα-satellite DNA is located in the centromere
region, and at least 33different alphoid subfamilies have been identiﬁed
[28]. Although some of these subfamilies are represented in a single
chromosome, others are common to a small groupof chromosomes. The
BLASTanalysis revealed that theα-satellite probe sequencewas focused
mainly in the centromere regions and was present in about 75% of
chromosomes (Supplemental Fig. 1C). Because these probes provided
good coverage of the human genome, theywere considered suitable for
Southern blot analysis.
2.2. Zta expression does not alter global cytosine methylation in
HONE-tetonZ cells
Repetitive elements are generally heavily methylated in normal
somatic tissues but are methylated to a lesser extent in malignant
tissues [29]. Furthermore, global genomic hypomethylation in repeatsequences and transposable elements is believed to result in chromo-
somal instability and increased mutation events that are commonly
found in human cancers [30]. Thus the methylation status in repetitive
sequences is the best indicator for the level of methylation in the whole
genome. To examinewhether Zta expression alters DNAmethylation in
repetitive sequences, we performed Southern blot analysis of genomic
DNA isolated fromZta−or Zta+using the LINE-1-, Alu-, andα-satellite-
speciﬁc probes. Similar levels ofmethylationwere observed for all three
repetitive elements independent of Zta overexpression (Fig. 1A). SINE-
Alu, LINE-1, and α-satellite methylation in Zta+ and Zta− cells was
quantiﬁed by densitometry; signal ratios from DNA digested byMspI to
that digested by HpaII were 16.878±0.1 and 19.037±4.93 (P=0.87),
16.879±4.26 and 17.043±2.89 (P=0.67), and 12.711±1.28 and
12.57±0.2 (P=0.94), respectively (Fig. 1B). These data suggested that
expression of Zta protein in these cells did not change the distribution of
cytosine methylation in repetitive sequences.
2.3. Zta expression has no effect on the pattern of X chromosome
methylation in HONE-tetonZ cells
The process of X chromosome inactivation is a compensatory
mechanism that promotes equivalent levels of X-linked gene products
through silencing of most genes on the inactivated X chromosome;
the cytosine residues within genes on the inactivated X chromosome
are methylated. In embryonic cells, X chromosome inactivation is
random,with an equal probability for inactivation of thematernally or
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repetitive sequences is associated with X chromosome inactivation in
females, digestion of genomic DNA with methylation-sensitive
enzymes followed by PCR ampliﬁcation of digestion products with
primers ﬂanking the digestion sites (HUMARA analysis) allows
identiﬁcation of transcriptionally active (unmethylated) and inactive
(methylated) X chromosomes in heterozygous female subjects
[33,34]. In theory, a ratio close to 0.5 indicates random inactivation
of both X chromosomes [34].
To examine whether Zta expression alters the X chromosome
methylation pattern, we performed HUMARA analysis of genomic
DNA isolated from Zta− or Zta+ cells using ﬂuorescent dye-labeled
PCR ampliﬁcation primers and quantiﬁed the ampliﬁcation products
using an automated genetic analyzer (ABI PRISM 310 Genetic
Analyzer). The primers generated two peaks (one for each allele)
from genomic DNA and one peak (single allele) from the control
human male genomic DNA before HpaII digestion (Fig. 2A), but
complete loss of one of the two peaks in the HpaII-digested DNA
(Fig. 2B) was observed, indicating non-random inactivation of the
X chromosome. However, because the patterns were similar in both
Zta+ and Zta− cells, these results suggested that expression of Zta did
not affect the methylation pattern on the X chromosomes.
2.4. Methylation of the IGF2/H19 imprinting control region was not
changed in Zta-expressing HONE-tetonZ cells
Genomic imprinting is an epigenetic phenomenon resulting in the
expression of only one parental allele; the other is silenced. Loss of
imprinting is an epigenetic disruption that occurs more commonly
than conventional genetic mutations in human cancers. In fact, loss of
imprinting or reactivation of the maternal allele of IGF2 is associated
with an increase in IGF2 expression, which may subsequently play anFig. 2. HUMARA analysis of X chromosome inactivation in Zta-expressing cells.Samples co
combined with control genomic DNA isolated from a human male and then treated with
ampliﬁcation of the X chromosome-speciﬁc androgen receptor gene (male-speciﬁc peaks are
with the methylation-sensitive enzyme HpaII. A complete loss of one of the two peaks in the
Zta+ and Zta− cells.important role in the onset of human cancers [35]. To examine
whether Zta expression alters the balance of genomic imprinting,
resulting in aberrant IGF2 expression, quantitative real-time PCR was
performed to measure the methylation of the imprinting control
region (ICR) of IGF2/H19 in Zta+ and Zta− cells (Fig. 3A).
Undigested or HpaII-digested genomic DNA isolated from Zta− or
Zta+ was subjected to PCR ampliﬁcation using the TaqMan Assay.
Undigested DNA mimics a fully methylated DNA template (methyl-
ation level=100%); comparison of ampliﬁcation products (ΔCt
values) from digested DNA and undigested DNA thus represents the
relative methylation within the region of interest. The ΔΔCt values
from Zta+ and Zta− samples were 2.43±0.12 and 2.83±0.06,
respectively (Fig. 3B). Using 2−(ΔΔCt±SD) formula, these numbers
reﬂect methylation levels of 18.6% (17.1–20.2%) in Zta+ cells and 14%
(13.4–14.6%) in Zta− cells. The levels of methylation were substan-
tially below 50% in both cell lines, indicating that the ICR is highly
methylated in HONE-tetonZ cells. However, expression of Zta did not
alter methylation of the IGF2/H19 ICR (P=0.56).
2.5. The ZREs of EGR1 promoter were not methylated in Zta-expressing
HONE-tetonZ cells
Zta is the only known example of a viral transcription factor that
binds to the methylated response elements (ZREs) in the BRLF1
promoter (Rp) [17]. In addition, our previous study showed that Zta
binds to the ZREs within the EGR1 promoter [19] and triggers EGR-
1expression (Supplemental Fig. 1). To examine whether the EGR1
promoter is methylated in HONE-tetonZ cells, we performed
methylation-sensitive qRT-PCR to amplify sequences near the EGR1
ZRE region (Fig. 3A). In contrast to the ICR of IGF2/H19, the Ct value
from ampliﬁcation of the EGR1 promoter increased by more than
10 cycles after genomic DNA was digested with HpaII, suggesting thatntaining genomic DNA isolated from Zta+ (upper panel) or Zta− (lower panel) were
out (A) or with (B) HpaII and then subjected to HUMARA analysis. Peaks represent
indicated with arrowheads) and are reduced in size when the genomic DNA is digested
HpaII-digested DNAs indicated non-random inactivation of the X chromosome in both
Fig. 3. Methylation-sensitive quantitative real-time PCR analysis of IGF2/H19 and EGR1 in Zta-expressing cells. (A) qPCR primers (arrows) were designed to speciﬁcally amplify
HpaII-containing sequences in the ICR of IGF2/H19 or near the ZRE (red bars) in the EGR1 promoter. The red vertical arrows indicate HpaII-digestion site of each sequence. Gray bars
show the target location of the TaqMan probe. The ACTB gene was used as an internal control lacking HpaII digestion sites. Ampliﬁcation plots for methylation-sensitive TaqMan real-
time PCR analysis of (B) IGF2/H19 and (C) EGR1 before (leftmost curves) and after (rightmost curves) HpaII digestion of genomic DNA isolated from Zta− (green) or Zta+ (blue)
cells. The left two lines indicate the two cell lines without HpaII treatment, and the right two lines indicate the two samples with HpaII treatment in panels B and C. (D) Bisulﬁte
sequencing demonstrated unmethylated sequences of EGR1 ZRE in both Zta+ (upper panel) and Zta− (lower panel) cells. A fragment of sequences spanning two HpaII-digestion
sites and the ZREs is shown. The CpG site within EGR1 ZRE is marked in red color. Unmethylated Cs (red underline) become Ts upon bisulﬁte modiﬁcation.
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enzyme (Fig. 3C). As the results only indicated that cytosine
sequences near the EGR1 promoter ZREs are not protected by
methylation in both Zta+ and Zta− cells, we further examined the
sequences at the CpG site of EGR1 ZRE after bisulﬁte conversion. The
sequencing data conﬁrmed the unmethylated CpG site of EGR1 ZRE
in both Zta+ and Zta− cells (Fig. 3D). These results indicated that
CpG site of EGR1 ZRE is not protected by methylation in both Zta+
and Zta− cells.2.6. The level of genomic 5-methylcytosine content in HONE-tetonZ cells
was independent of Zta expression
Changes in the relative percentage of methyl-cytosine (mC) in
genomic DNA reﬂect changes in chromatin structure. Since tumor
development can be discerned from the mC content, quantiﬁcation of
total genomic DNA methylation by HPCE has been utilized to
determine the mC content and reﬂect methylation level in tumor
DNA from cancer patients [36].
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we evaluated the globalmCcontent in genomicDNA isolated fromZta+
and Zta− cells using HPCE (Fig. 4A). As illustrated in Fig. 4, the
proportions of mC relative to total cytosine [5mdC/(5mdC+ dC)] were
4.60% and 4.17% in Zta− and Zta+ cells, respectively. Although the
difference in levels of mC between Zta− and Zta+ cells did not reach
statistical signiﬁcance (P=0.409; Figs. 4B–D), themC content is indeed
slightly lower in the Zta+ cells.
2.7. Zta expression does not alter expression of DNMTs or LINE ORFs
DNA methylation is established and maintained by DNMTs. To test
whether Zta overexpression in HONE-tetonZ cells alters expression ofFig. 4. HPCE analysis of global methyl-cytosine content in genomic DNA isolated from Zta-ex
cytosine). HPCE analysis of genomic DNA isolated from Zta+ (B) or Zta− (C) cells. Peaks rep
the ratio of mC to total cytosine in genomic DNA isolated from Zta+ or Zta− cells. Data reDNMTs, we performed Western blot analysis of three representative
DNMTs: DNMT1, DNMT3A and DNMT3B. In addition, the expression of
the LINE-1 ORFs was also examined. The expression of PCNA, was
analyzed to verify cell proliferation, and pan-actin was analyzed a control
for protein loading (Fig. 5A).
The normalized expression levels of DNMT1, DNMT3A and DNMT3B
were 0.6±0.12, 0.27±0.05 and 0.68±0.05, respectively, in Zta+ cells
and 0.59±0.19, 0.29±0.006 and 0.83±0.13, respectively, in Zta− cells.
Therefore theexpressionofDNMT1,DNMT3AandDNMT3Bwas similar in
Zta+ and Zta− cells (P=0.78, 0.50 and 0.22, respectively) (Fig. 5B). In
addition, expression of the LINE-1 ORF1 in Zta+ and Zta− cells was
comparable (P=0.23; Fig. 5B); the expression of LINE-1 ORF2 was
detected in control NT2 cells but not in Zta+ or Zta− cells (data notpressing cells. (A) HPCE standards to identify the elution proﬁles of C, and mC (methyl-
resenting cytosine (c) and mC content are highlighted. (D) Histogram representation of
ﬂect the mean±SEM from three independent experiments.
Fig. 5.Western blot analysis of methylation-related proteins in Zta-expressing cells. (A) The expression of DNA methyltransferases (DNMT1, DNMT3A and DNMT3B), LINE-1 ORF1
(ORF1), and proliferating cell nuclear antigen (PCNA) were determined byWestern blot analysis from Zta− or Zta+ cells. NT2 was used as a positive control. (B) DNMT1, DNMT3B,
ORF1 and PCNA expression in Zta+ and Zta− cells was quantiﬁed and normalized by pan-actin. Data reﬂect the mean±SEM from three independent experiments.
210 Y.-F. Chen et al. / Genomics 97 (2011) 205–213shown). Taken together, these data indicate that Zta expression does not
affect expression of DNMTs or expression of LINE-1 ORFs in HONE-tetonZ
cells.
3. Discussion
To the best of our knowledge, this is the ﬁrst study examining the
methylation status of the host genome in a Zta-expressing cell model.
It is believed that periodic lytic replication is required for the lifelong
persistence of EBV in most EBV-positive adults [37]. In addition, high
antibody titers to lytic antigens correlate well with increased risk of
NPC, suggesting that lytic replication may increase the probability of
an EBV-associated malignancy [38]. Changes in human DNA methyl-
ation patterns are an important feature of cancer development and
progression. Although the role of alteration of methylation patterns in
the host genome in association with EBV infection has been
extensively examined [22,23,39], few studies have documented the
DNAmethylation status of the host genome and the expression of host
DNMTs upon EBV reactivation. Because no single method has
emerged as the “gold standard” for quantitative assessment of
methylation levels in cells, several approaches to evaluate DNA
methylation on a whole-genome scale were developed and applied in
this study. We found that global DNA methylation, based on X
chromosome inactivation, methylation of repetitive elements and
imprinting genes, and total mC content, did not change upon Zta
induction in EBV-negative NPC cells. The expression of DNMTs was
also not affected by ectopically expressed Zta. Together, these
methods provide a comprehensive view of the methylation status in
host cells in response to Zta overexpression and suggest that the
methylation level of genomic DNA was unaffected under ectopic
expression of the EBV transactivator Zta.
Although Zta expression does not induce changes in global DNA
methylation in the host genome, Zta may activate cellular genes by
interacting with speciﬁc methylated promoter sequences. Our previ-
ous study showed that Zta binds to the ZRE in the EGR1 promoter and
triggers EGR1 expression [19]. Sequence analysis revealed a ~2.5-kb
CpG island located in the EGR1 promoter region (data not shown).
Furthermore, a recent study indicated that Zta transactivation of a
reporter construct driven by the EGR1 promoter is enhanced by
methylation [40]. Therefore, we investigated themethylation status of
the CpG island in the EGR1 promoter region to examine themechanism underlying Zta-mediated EGR1 expression. Methylation-
speciﬁc qPCR and bisulﬁte sequencing demonstrated that the CpG
island in the EGR1 promoter region was unmethylated in HONE-
tetonZ NPC cells and that induction of Zta expression did not overturn
themethylation status in these cells. It has been shown that the lack of
EGR1 expression in the immature B cell line WEHI-231 and in
tolerance-sensitive bone marrow-derived B cells is caused by speciﬁc
methylation of the EGR1 gene [41]. Furthermore, Kalla et al. [26]
showed that Zta can bind to unmethylated EBV genome but the
binding was enhanced when the genomic locations are methylated.
These studies suggest that Zta binds to both methylated and
unmethylated ZRE sequences. Taken together, our data indicate that
Zta can induce EGR1 expression even when EGR1 promoter is
constitutively unmethylated in HONE-tetonZ cells.
Zta is a transactivator that belongs to the basic leucine zipper (bZIP)
family. Structural similarity of Zta and AP-1 suggested that Zta can bind
directly to the consensus AP-1 site and induce gene expression [42].
Because Zta is the key transactivator that triggers the lytic cascade and
leads to EBVreactivation [10], it is not surprising thatZta targetsnot only
viral genes but also many cellular genes including TGF-β1 and the TGF-
β-inducible gene βig-h3 [43]. Indeed, studies have revealed that
interaction between Zta and target host genes inﬂuences many cellular
functions. For example, Zta interacts with genes in the interferon
signaling pathway [44] and regulatesmajor histocompatibility complex
class I antigen presentation [45]. Furthermore, recent study using a
human oligonucleotide DNA microarray identiﬁed up- or down-
regulation of a subset of pathogenically and clinically relevant host
cellular genes in reactivated EBV-associated SNK/T cells [46]. Although
our study indicates that Zta neither alters global DNA methylation in
host cells nor binds to methylated cellular genes (i.e., EGR1), our data
cannot exclude that Zta expression may affect DNA methylation at
speciﬁc genes' promoter thus altering their expression. Nevertheless,
Zta does function as a transcription factor by binding target gene
promoters and inducing gene expression during reactivation. Results
from our study suggests that the altered expression of many cellular
genes upon EBV reactivation or Zta expression may simply result from
direct binding of Zta to target gene promoters via a consensus AP-1
binding site. Thus a global investigation of cellular genes inﬂuenced by
Zta anddetailed exploration of EBValteration of cell activities during the
lytic cycle will be required to elucidate the mechanism of EBV
persistence in host cells.
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Epigenetic dysregulation plays signiﬁcant role in oncogenesis.
Methylation changes in both global and targeted genes have been
attributed to EBV+ lymphomas and carcinomas (for review, see
reference [39]). These studies suggest the contribution of EBV genome
in the epigenetic dysregulation of genes involved in tumorigenesis.
Systemic analyses of epigenetic alterations under the expression of
speciﬁc viral gene thus may help to specify the contribution of EBV
genome. Although results from our study suggested that the expression
of major viral lytic protein Zta has no effect on changing DNA
methylation in the host genome, the comprehensive methods estab-
lished here provide a useful platform to investigate genomic methyl-
ation changes upon various conditions. Applying this system, we are
currently investigating the epigenetic inﬂuence of expression of other
viral genes in the EBV genome on the host cells. We anticipate that
results from these studieswill lead to a better understanding of the EBV
pathogenesis and may facilitate the development of new therapies.
5. Materials and methods
5.1. Cell lines and genomic DNA extraction
The HONE-tetonZ cell line was established from an EBV-negative
NPC-derived epithelial cell line [47]. Cells weremaintained in an RPMI
1640 medium supplemented with 10% fetal bovine serum (Hyclone
Laboratories, Logan, UT) at 37 °C with 5% CO2. In this study, we used
the HONE-tetonZ cells treated with 1 μg/ml doxycycline (Zta+) for
24 h to induce the Zta expression, and untreated HONE-tetonZ cells
(Zta−) to detect the global methylation status in these cells
(Supplemental Fig. 2). Genomic DNA was isolated from Zta+ and
Zta− cells using the PUREGENE DNA Puriﬁcation kit (Gentra System,
Minneapolis) according to the manufacturer's protocol.
5.2. Southern blot probes for the detection of repetitive DNA sequences
To evaluate global DNA methylation in the cells, DNA probes of
three repetitive elements, LINE-1, SINE-Alu, and alpha (α)-satellite,
were prepared for Southern blot analysis. The LINE-1 probe speciﬁc
for the L1 promoter region was designed according to the literature
[48]. For the SINE-Alu and α-satellite probes, human SINE-Alu and α-
satellite sequences were retrieved from RepBase version 8.12 (http://
www.girinst.org/Repbase_Update.html.l) and aligned using the Clus-
talW program (Supplemental Fig. 3). Using the Primer3 online service
program (http://frodo.wi.mit.edu/), primers for ampliﬁcation of
conserved sequences in the SINE-Alu and α-satellite repetitive
elements were designed and are shown in Supplemental Table 1.
Togenerate Southern blot probes, 50 nggenomicDNAwasampliﬁed
by PCRusing 0.25 μMprimers, 200 μMof each dNTP, 1.5 mMMgCl2, and
1.25 U of TaqDNA polymerase (Promega) in a ﬁnal volume of 25 μl. PCR
reaction conditions were as follows: 5 min at 95 °C, followed by
35 cycles at 95 °C for 30 s, 60 °C (for LINE-1 and α-satellite) or 63 °C
(for Alu) for 30 s, and 72 °C for 30 s, with a ﬁnal step at 72 °C for 10 min
followed by a 4 °C hold. PCR products were cloned into a TA-based
cloning vector (yT&A, Yeastern Biotech, Taipei, Taiwan) and trans-
formed into Escherichia coli DH5α. Positive colonies were selected by
blue/white screening, followed by DNA extraction and sequencing.
Hybridization probes were prepared from the resulting plasmid DNA
and labeled with DIG-11-dUTP using the DIG DNA labeling kit (Roche
Molecular Biochemicals, Mannheim, Germany) according to the
manufacturer's protocol.
5.3. Southern blotting
Since roughly 70% of the methylated CpG sites reside in the repetitive
sequences, the level and distribution of methylated CpG dinucleotideswithin the repetitive sequences of the genome (LINE-1, Alu, and
α-satellite) in response to Zta overexpression were determined by
comparison of Southern blot analysis followingMspI and HapII digestion
of genomic DNA isolated from Zta+ and Zta− cells. Ourmethod relies on
the fact that the restriction enzymes MspI and HpaII both recognize the
same sequence CCGG; but HpaII only digests unmethylated sequences at
the inner cytosinewhileMspI is insensitive to themethylationstatusof the
inner cytosine. When genomic sequences are not methylated, the
digestion patterns generated by these two enzymes are the same.
However, if the genomic sequences are protected bymethylation, the two
enzymes will generate different patterns in Southern blot analysis.
Genomic DNA (1 μg) from Zta+ and Zta− cells was digested with
MspI or HpaII endonuclease (New England Biolabs, Beverly, MA) at 37 °C
overnight. The enzymewas then inactivated at 65 °C for 20 min, and 0.5–
1.0 μg of each sample was subjected to 0.8% or 1.5% agarose gel
electrophoresis. DNA on the gels was denatured with 0.5 M NaOH and
then capillary-transferred onto a nylon membrane (Roche Molecular
Biochemicals).DNAwascross-linked to themembraneusingUV light, and
the membrane was hybridized with various probes using the DIG Easy
Hyb kit (Roche Molecular Biochemicals). Signals were detected using an
autoradiography ﬁlm (Hyperﬁlm-MP, Amersham International, UK).
Methylation levels were quantiﬁed using the AlphaImager 1200 (Alpha
Innotech; San Leandro, CA) spot density function. The ratio of hybridiza-
tion signals fromDNAdigested byMspI to that digested byHpaII indicated
the level of methylation; a high ratio indicated a high methylation level.
5.4. Protein preparation, immunoﬂourescence assay, and Western
blotting
Total cell lysates and nuclear extracts were prepared from cultured
cells using modiﬁed radioimmunoprecipitation buffer (RIPA buffer)
containing protease inhibitors and the NE-PRER Nuclear and Cyto-
plasmic Extraction Reagents (Pierce, Rockford, IL), respectively. The
total protein concentration of each sample was measured using the
Bradford assay and Coomassie Blue G-250 dye reagent (Bio-Rad,
Hercules, CA). For Western blot analyses, proteins were separated by
SDS-PAGE and transferred to a PVDF membrane (Amersham
Pharmacia, Buckinghamshire, UK). Membranes were blocked and
incubated with the following primary antibodies: anti-DNMT1
(Imgenex, San Diego, CA), anti-DNMT3A (ABCAM, Cambridge, UK),
anti-DNMT3B (ABCAM), anti-proliferating cell nuclear antigen
(PCNA; Calbiochem, Darmstadt, Germany), anti-EGR1 (Santa Cruz
Biotech, Santa Cruz, CA), anti-Zta [49], anti-β-actin (Chemicon,
Temecula, CA), and anti-pan-actin (Cell Signaling, Danvers, MA).
The LINE-1 ORF1 antiserum was a kind gift from Dr. Goodier [50]. The
membranes were then incubated with a horseradish peroxidase-
conjugated secondary antibody for 1.5 h and developed using the
chemiluminescence detection system (PerkinElmer Life Science,
Boston, MA) and the ECL Plus kit (Amersham, Piscataway, NJ).
Western blots were quantiﬁed using the AlphaImager 1200 spot
density function, and protein expression was normalized to that of
pan-actin or β-actin.
To detect the proportion of Zta expression in doxycycline-induced
HONE-tetonZ cells, immunoﬂourescence assay was carried out using
anti-Zta monoclonal antibody 4F10 [49]. The secondary antibody was
Alexa594-conjugated goat anti-mouse IgG (Invitrogen). Nuclei were
stained with DAPI. After mounting, the slides were examined under a
ﬂuorescence microscope (Olympus).
5.5. Methylation-speciﬁc quantitative PCR (qPCR)
The methylation-speciﬁc qPCR procedure was developed to deter-
mine the level of DNA methylation in any given region using a high-
throughput real-timePCRsystem(ABIPRISM7900;AppliedBiosystems,
Foster City, CA). The procedure required two sequential reactions
(Fig. 4). In the ﬁrst reaction, 1 μg genomic DNA was digested with the
212 Y.-F. Chen et al. / Genomics 97 (2011) 205–213methylation-sensitive endonuclease HpaII to distinguish methylation-
protected DNA sequences from non-methylated DNA sequences.
Digested DNAs were puriﬁed and subjected to a second reaction in
which the target gene fragment was quantitatively ampliﬁed by PCR
using the TaqMan Assay (TaqMan Assay-by-Design probe; Applied
Biosystems). Primer and probes were targeted to sequences encom-
passing at least one HpaII recognition site. Therefore, when DNA is
protected by methylation, it is refractory to HpaII digestion and the
target sequence(s) can be ampliﬁed by PCR. However, if theDNA is non-
methylated,HpaIIdigestion occurs and the resultingDNA fragmentswill
not be ampliﬁed. An amplicon containing noHpaII recognition sites was
designed based on the sequence of beta-actin (ACTB) gene as a
calibration standard for the comparative ΔΔCt method.
Each ampliﬁcation reaction was performed in triplicate in separate
wells to quantify target gene ampliﬁcation relative to ACTB ampliﬁca-
tion. Data reﬂectΔCt for normalized amplicon copy numbers or asΔΔCt
forΔCt comparisons between Zta+ and Zta− cells. Overall methylation
levels reﬂect ampliﬁcation of target genes in HpaII-treated relative to
HpaII-untreated genomic DNA and were determined by 2−(ΔΔCt±SD)
[51].
5.6. Bisulﬁte sequencing
One μg of extracted DNA was treated with sodium bisulﬁte to
convert all unmethylated, but not methylated, cytosines to uracil.
Bisulﬁte conversion was carried out using the EZ DNA Methylation Kit
(ZYMO Research Co., Orange, CA), according to the manufacturer's
instruction. The converted DNA was stored at −70 °C until use. 1 μl
(~50 ng) of sodium bisulﬁte-converted DNA was added into a 20 μl
reaction mixture that contains 0.2 μl of Taq DNA polymerase (5 U/μl,
DNApolymerase; Promega), 2 μl of the supplied 10×PCRbuffer, 1.2 μl of
MgCl2 (25 mM), 1.6 μl of dNTPs (2.5 mM) and 0.4 μl of the
corresponding forward and reverse primers (10 μM). Thermocycling
conditions used were as follows: one cycle at 95 °C for 5 min, followed
by 35 cycles of 95°Χ for 30 s, 49 °C for 30 s and 72 °C for 30 s,with a ﬁnal
extension cycle of 72 °C for 10 min. PCR products were cloned into a TA
cloning system ( Invitrogen) for sequencing. The bisulﬁte PCR primers
used in this study were as follows: forward primer, 5′-
TTTGGGTTTTTTTAGTTTAGTTTA-3′; reverse primer, 5′-AATACTACC-
CAAATAAAAATTATTCC-3′.
5.7. Quantiﬁcation of total 5-methylcytosine content in genomic DNA by
high-performance capillary electrophoresis (HPCE)
Quantiﬁcation of the degree of genomic DNA methylation was
carried out as described [36]. Brieﬂy, 40 μg genomic DNA (1 μg/μl) was
hydrolyzed in a sealed ampoule with 2 ml 88% v/v formic acid at 140 °C
for 90 min. After hydrolysis, samples were dried and re-dissolved in
30 μl Milli-Q-grade H2O. HPCEwas performed using an uncoated fused-
silica capillary (75 μminnerdiameter) of 44.5 cmeffective length in a CE
system (P/ACTM MDQ, Beckman-Coulter). Samples were separated at
25 °C and 20 kV in running buffer (20 mM NaHCO3 pH 9.2 containing
80 mMSDS). Adenine (A), thymine (T), guanine (G), uracil (U), cytosine
(C) and 5-methyl-cytosine (mC) were used as standards (Sigma, St.
Louis, MO). On-column absorbance was monitored at 254 nm. Before
each analysis, the capillary system was conditioned by washing with
0.1 MNaOH for 3 min followed by equilibration with running buffer for
3 min. The relative methylation of each DNA sample was quantiﬁed
based on the percentage of mC relative to total cytosines as follows:
mC peak area×100/ (C peak area+ mC peak area). Data reﬂect
means±SEM from three analyticalmeasurements of triplicate samples.
5.8. Human androgen receptor assay
The human androgen receptor assay (HUMARA) is a polymerase
chain reaction-based X chromosome inactivation assay. HUMARAanalysis was performed as reported [34], with some modiﬁcations.
Brieﬂy, 500 ng genomic DNA isolated from Zta+ or Zta− cells and
from a single male individual was digested with 5 U HpaII at 37 °C
overnight; reactions were terminated by heat-inactivation at 65 °C
for 20 min. The DNA was puriﬁed using phenol/chloroform extrac-
tion followed by ethanol precipitation. PCR ampliﬁcation of the
human androgen receptor gene was performed using the primers
suggested by Jovanovic et al. [33], except that the forward primerwas
5′ end-labeled with the ﬂuorescent dye FAM; the PCR ampliﬁcation
product was detected using an ABI PRISM 310 Genetic Analyzer
(Applied Biosystems). The predicted length of the ampliﬁed product
was 222+3n bp (n=trinucleotide repeat number). Because ge-
nomic DNA from human males contains a single unmethylated X
chromosome, it should be completely cleaved by HpaII and therefore
refractory to PCR ampliﬁcation. Thus an equal amount of genomic
DNA from a human male (obtained from a population study) was
added to eachHUMARA sample as a positive control forHpaII activity.
Data reﬂect means±SEM from three independent experiments
performed in triplicate.
5.9. Statistical analysis
All data are presented as the mean±SEM, and signiﬁcance was
analyzed by paired t-tests and nonparametric tests using the
GraphPad Prism 3.0 package (GraphPad, San Diego, CA). A P-value
of b0.05 was considered statistically signiﬁcant.
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